EUCTR2010-021922-36-DK进行中（未招募）1 期
Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.
Department of Nephrology, Rigshospitalet, University of Copenhagen0 个研究点开始时间: 2011年5月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Male or female; aged 18-85 years
- •· Chronic severely impaired kidney function treated with chronic maintenance
- •· Type 2 Diabetes
- •· Male or female; aged 18-85 years
- •· Normal kidney fuction
- •· Type 2 Diabetes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Group 1 and 2
- •· Type 1 diabetes mellitus
- •·Chronic pancreatitis / previous acute pancreatitis
- •·Known or suspected hypersensitivity to trial product(s) or related products
- •·Treatment with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors or other drugs, which in the Investigator’s opinion could interfere with glucose or lipid metabolism 90 days prior to screening
- •·Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder which in the investigators’ opinion could interfere with the results of the trial
- •·Inflammatory bowel disease
- •·Cardiac disease defined as: decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
- •·Body mass index = 18.5 kg/m2 or = 50.0 kg/m2
- •·Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods
- •·Clinical signs of diabetic gastroparesis
- •·Impaired liver function (transaminases >two times upper reference levels)
- •·Receipt of any investigational product 90 days prior to this trial
- •·Known or suspected abuse of alcohol or narcotics
- •·Screening calcitonin =50 ng/l
- •·Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2
研究者
相似试验
进行中（未招募）
1 期
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetesMedDRA version: 16.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2012-005778-74-ITovo Nordisk A/S804
已完成
3 期
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes; A 26-weeks randomised, insulin capped, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trial10018424diabetesNL-OMON40721ovo Nordisk30
进行中（未招募）
不适用
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-005778-74-DKovo Nordisk A/S804
进行中（未招募）
不适用
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetesDiabetes Mellitus, Type 1EUCTR2012-005778-74-BEovo Nordisk A/S804
进行中（未招募）
1 期
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetesDiabetes Mellitus, Type 1EUCTR2012-005778-74-FRovo Nordisk A/S835